TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Efficacy of Two Oral Rehydration Solutions, With or Without the Probiotic Lactobacillus Reuteri DSM 17938 and Zinc, on the Duration and Severity of Acute Gastroenteritis in 6 - 36 Months Old Children in Out-patient Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 6 - 36 months of age~* 3 or more loose or watery stools during the past 24 hours~* Available throughout the study period~* Parents or legal guardians are able to give written informed consent to participation in the study.~Exclusion Criteria:~* Diarrhoea with a duration of \>48 hours at the time of recruitment.~* Clinical signs of severe dehydration at the time of recruitment or in need of hospitalisation.~* Clinical signs of a coexisting severe acute systemic illness (meningitis, sepsis, pneumonia).~* Primary or secondary immunodeficiency.~* Severe chronic diseases including cystic fibrosis, diabetes mellitus, neurodevelopmental delay or severe gastrointestinal disorders.~* Use of probiotics in the previous 2 weeks before recruitment.~* Use of antibiotics in the previous 2 weeks before recruitment.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 36 Months
- Healthy Volunteers: f

Study Arms:
- ORS with probiotic and zinc (Type: EXPERIMENTAL): Oral rehydration solution with freeze-dried Lactobacillus reuteri DSM 17938 and zinc sulphate
- Standard ORS (Type: PLACEBO_COMPARATOR): Standard oral rehydration solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Stress Index to Individualize Mechanical Ventilation in ARDS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to the Intensive Care Unit~* Receiving invasive mechanical ventilation via endotracheal or tracheostomy tube~* Presence of ARDS by Berlin Criteria (acute onset bilateral pulmonary infiltrates incompletely explained by left heart failure together with a PaO2/FiO2 of \<300 or SpO2/FiO2 \<315)~Exclusion Criteria:~* Inability to obtain surrogate consent~* Presence of specified comorbidities:~  1. pregnancy~ 2. pre-existing severe chronic obstructive pulmonary disease, defined as FEV1 documented \< 1L or baseline hypercapnia~ 3. cerebral edema~ 4. known intra-cranial abnormality~ 5. acute coronary syndrome~* Endotracheal or tracheostomy cuff leak~* Chest tube with persistent air leak~* Severe hemodynamic instability (defined as attending judgment that the patient is unable to safely tolerate ventilator manipulations)~* Presence of spontaneous respiratory activity as evidenced by examination of the ventilator waveform tracing~* Intrinsic PEEP of \> 5 cmH2O~* Assessment of study staff or patient's attending physician that the patient would not be a good study participant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: DLBS1033 for Acute Ischemic Stroke Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent from the patients or patients' legally acceptable representatives (must be obtained before any trial related activities).~* Male or female subjects with age of \>18 years at Screening.~* Patients clinically diagnosed having acute ischemic stroke attack and confirmed by CT scan.~* Patients with cerebral infarction subtypes of PACI or LACI as classified by Bamford criteria.~* Patients with moderate condition based on National Institutes of Health Stroke Scale (NIHSS) score of 5-15.~* Patients present at hospital and receiving first dose of study medication within 72 hours after the onset of the stroke symptoms.~* Able to take oral medication.~Exclusion Criteria:~* For females of childbearing potential: pregnancy and lactation period.~* History of hemorrhagic stroke within the last 3 months.~* Patients with seizure at the onset of stroke or with regular medication for seizure/epilepsy.~* Current or regular use (within the last 1 month) of oral anticoagulants, antiplatelets other than study medication, and herbal medicines.~* Patients who have received tissue plasminogen activator (TPA) within 24 hours to Screening.~* History of serious head injury within the last 3 months.~* History of major surgery within the last 3 months.~* Recent serious cardiovascular conditions, such as myocardial infarction and heart atrial fibrillation as demonstrated by electrocardiography (ECG).~* History of congestive heart failure and aortic dissection.~* Presence of severe renal and hepatic dysfunction, defined as serum creatinine level \> 3x upper limit of normal (ULN) or history of hemodialysis, and any of serum ALT, AST, Gamma-GT level of \> 3x ULN, respectively.~* Presence of acute SIRS.~* Presence of chronic infections.~* Patients with higher risks of bleeding.~* Subjects with uncontrolled hypertension (systolic blood pressure \> 185 mmHg or diastolic blood pressure \> 110 mmHg).~* Subjects with random plasma glucose ≥180 mg/dL and HbA1c ≥ 7.0% at Screening.~* Known or suspected hypersensitivity to the trial product or related products.~* Participation in any other clinical studies within 30 days prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 3 x 1 tablet, given everyday for 28 days of study period
- DLBS1033 (Type: EXPERIMENTAL): DLBS1033 enteric-coated tablet 3 x 490 mg daily, given everyday for 28 days of study period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Girls ages 8 to 14~* Tanner 1-3 pubertal stage~* Pre-menarchal~* Normal screening labs~Exclusion Criteria:~* Abnormal screening labs~* Congenital adrenal hyperplasia~* Hyperandrogenism (e.g., hirsutism, elevated free testosterone level)~* Hemoglobin \<12 mg/dL or hematocrit \< 36% (Subjects will be offered the opportunity to take iron supplementation for 60 days if their hematocrit is slightly low (33-36%) (suggestive of iron deficiency anemia) and will then return for retesting of their hemoglobin/hematocrit.)~* Weight \< 31 kg~* History of peanut allergy, deep venous thrombosis, breast cancer, endometrial cancer, or cervical cancer~* On hormonal medications (including oral contraceptive pills) or on medications known to affect the reproductive axis within 3 months of the study~* Pregnant or breast feeding~* Participation in a research study within the past 30 days that involved taking a study drug.~* Participation in a research study that involved taking up to or greater than 473 ml's of blood within the past 60 days.~* Cigarette smoking~* History of surgery that required bedrest within the past 30 days~* Family history of hypercoagulability or unexplained thromboembolic disease (not in setting of bedrest, surgery, or malignancy)~* In order to ensure an adequate number of younger girls, no more than 4 enrolled subjects will be Tanner stage 3

- Gender: FEMALE
- Minimum Age: 8 Years
- Maximum Age: 14 Years
- Healthy Volunteers: t

Study Arms:
- Progesterone, estrace (Type: EXPERIMENTAL): oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr to achieve mean plasma concentrations over the range of 2-8 ng/ml for seven days~oral estrace, 0.5-1 mg once a day for seven days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Acupuncture on Symptoms, Gastric Emptying Rate and Glucose Control in Patients With Diabetic Gastroparesis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18-80,~* Diabetic patients of over 10 years duration with impaired glucose control, after at least 6 months of accepted treatment in a Diabetes Clinic by the study staff before inclusion in the study, who exhibit symptoms which could signify the possibility of diabetic gastroparesis.~Exclusion Criteria:~* Known hyperprolactinemia, systemic or localized neurological disturbances (myopathy, multiple sclerosis, Parkinson's disease, myelopathy), with the exception of diabetic neuropathy, past stomach or esophagus surgery, pregnancy, inability to sign Informed Consent, fear of acupuncture, limb amputation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Motillium (Type: ACTIVE_COMPARATOR): 20 mg motilium thrice daily for 12 weeks.
- Acupuncture (Type: ACTIVE_COMPARATOR): Acupuncture treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of Aprotinin in Advanced Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a histologically or cytologically proven metastatic breast cancer.~* Patients with at least one bidimensionally measurable lesion (diameter \> 1 cm), or an evaluable bone lesion that will not undergo biopsy.~* Age \> 18 years.~* Life expectancy of at least 6 months.~* ECOG performance status 0-3.~* Screening laboratories within the following parameters: ANC \> 1500 cells/mm3, Platelets \> 100,000 cells/mm3, AST \< 2 x upper limit of normal, Bilirubin \< 1.5 x upper limit of normal, Calculated creatinine clearance \> 30 cc/min by the Cockroft and Gault equation.~* Concurrent treatment with hormonal therapy or trastuzumab is allowed.~* Patients must be post-menopausal (either as a result of surgery, or amenorrhea for at least 12 consecutive months), or they must be practicing either abstinence, an adequate method of contraception (intrauterine device or barrier contraception), or their sexual partner must be sterile. Women who are pregnant, breast-feeding, or who are fertile and not practicing an adequate means of contraception will be excluded.~* Patients must have a central venous catheter.~* Patients must be able to give informed consent indicating that they are aware of the investigational nature of this study.~Exclusion Criteria:~* No known CNS metastases.~* No treatment with cytotoxic chemotherapy allowed within 21 days of treatment with Aprotinin.~* No treatment with investigational agents allowed within 21 days of treatment with Aprotinin.~* No severe cardiovascular disease including unstable heart rhythm, uncompensated congestive heart failure, unstable angina or myocardial infarction within 6 months.~* No bleeding diathesis or coagulopathy including concomitant use of anticoagulants for thromboembolic disease~* No active anticoagulant therapy (including antiplatelet agents) for at least ten days.~* No active, uncontrolled bacterial, viral or fungal infection.~* No patients who are known or expected to be allergic to aprotinin, or who have received prior aprotinin.~* No patient with chronic systolic blood pressure (SBP) \< 90 mm Hg. If the (SBP) is \< 90 mm Hg on the day of treatment intravenous fluid may be administered to restore intravascular volume, if clinically indicated. In such case, if IV fluid corrects the SBP then the study drug may be given

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab (Avastin) Induced Hypertension and Correlation With Tumor Response, a Chart Review

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients treated with bevacizumab, with or without chemotherapy, with a wide variety of metastatic malignancies.~* Patients with and without pre-existing hypertension treated with bevacizumab plus or minus chemotherapy with a wide variety of metastatic malignancies.~Exclusion Criteria:~* Not specified.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~18 ≤ age ≤ 75 years old, male or female is not limited; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 Life expectancy of ≥ 12 weeks Pathologically confirmed advanced pancreatic cancer defined as non-operable in a curative intent, locally recurrent, or metastatic disease.~Exclusion Criteria:~adjuvant treatment with gemcitabine within 6 months prior to the first dose; Radiotherapy and anti-cancer Chinese patent medicine treatment were performed within 4 weeks before the first dose; Gastrointestinal diseases that could affect the absorption of Z650, (e.g., serious swallowing obstruction, chronic diarrhea, bowel obstruction); Doppler ultrasound evaluation of Left ventricular ejection fraction \< 50%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- z650 and Gemcitabine (Type: EXPERIMENTAL): Z650:250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal Gemcitabine: intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle FOR the 4-6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: NEIVATECH Virtual Reality-based System for Amblyopia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged between 7 and 15 years.~* VA in the amblyopic eye \< 0.1 logMAR units.~* Interocular difference in VA ≥ 1 logMAR line.~* Interocular difference in espherical equivalent ≥ 1 D.~* Interpupillary distance (IPD) between 60.7 and 73.5 mm.~* Use of best refractive correction for at least 2 months prior to inclusion.~* Lack of response or therapeutic adherence to conventional occlusion therapy.~* Willingness to attend all the active vision therapy sessions and/or visits of the study.~* No history of previous treatment for amblyopia other than optimal refractive correction for at least 2 months prior to inclusion.~Exclusion Criteria:~* Active eye disease.~* Previous ocular surgery.~* BCVA in the amblyopic eye of ≥ 0.70 logMAR.~* Presence of cognitive impairment or neurological or psychiatric disorders.~* Presence of irregular cornea due to astigmatism or ectatic corneal disease.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Active group (Type: EXPERIMENTAL): 18 half-hour in-office active vision therapy sessions with the NEIVATECH Virtual Reality-based system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Transgender Therapy on Muscle, Fat and Tissue Receptors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with gender incongruence by a mental health professional and willing to start gender affirming therapy~Exclusion Criteria:~* Used hormone therapy in last 6 months,~* Pregnancy,~* Planning to have biological children in the next one year,~* HIV Additional exclusion criteria for transmen: 1) hematocrit \>50% for transmen, 2) transmen with allergy to cottonseed oil (component of intramuscular testosterone injection), 3) uncompensated heart failure, 4) renal failure Additional exclusion criteria for transwomen: 1) allergy to castor oil (component of intramuscular estradiol injection), 2) Known or suspected estrogen-dependent neoplasia, 3) Active deep vein thrombosis, pulmonary embolism or a history of these conditions, 4) Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction), 5) Liver enzymes (AST or ALT) \>3 times the upper limit of normal, 6) Known or suspected pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: None

Study Arms:
- Transmen (Type: None): Subjects starting testosterone therapy as part of standard of care for gender incongruence
- transwomen (Type: None): Subjects starting estradiol therapy as part of standard of care for gender incongruence

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has a diagnosis of AD or Mild Cognitive Impairment (MCI) due to AD.~* The patient has evidence of an abnormal amyloid and tau status, consistent with AD, by means of a positive CSF test at screening~* The patient is aged ≥50 and ≤85 years. If a woman, the patient must be post-menopausal.~Exclusion Criteria:~* The patient has participated in a clinical study where he/she has received passive or active anti-Aβ immunotherapy or other active immunisation for the treatment of AD.~* The patient has, in the investigator's opinion, evidence and/or history (clinically or on MRI) of any clinically significant neurodegenerative disease, serious neurological disorder, other intracranial or systemic diseases or conditions resulting in a definite or probable diagnosis of Major or Mild Neuro-Cognitive disorder other than AD, per DSM-5® criteria.~Other in- and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 - dose regimen 1 (Type: EXPERIMENTAL): Cohort 1: encompasses patients enrolled prior to the PA1
- Cohort 2 - dose regimen 2 (Type: EXPERIMENTAL): Cohort 2: 10 patients who will receive one administration of booster vaccine prior to the first IMP administration
- Cohort 2 - dose regimen 3 (Type: EXPERIMENTAL): Cohort 2: 10 patients who will not receive a booster vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Variability of the Autonomic Nervous System (ANS) During Cluster Headache (CH).

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient over 18 years of age~* Affiliated or entitled to a Social Security scheme~* Resident in the territories of the hospital grouping of Loire territory (located less than 50 km away)~* Whose diagnosis of episodic or chronic Cluster Headache (CH) has been confirmed according to International Classification of Headache Disorders (ICHD)- 3 criteria~* With a regular sinus rhythm and heart rate~Exclusion Criteria:~* Conditions contraindicating the use of injectable sumatriptan~* Conditions likely to affect the Autonomic Nervous System (ANS): dysautonomic sensory neuropathies, sleep apnea syndrome, etc.~* Cognitive or language disorders that may interfere with pain assessment and seizure follow-up.~* Patients taking treatments that may modify the Autonomic Nervous System (ANS): catecholamine (adrenaline, noradrenaline, dopamine), B-stimulants (isoprenaline, dobutamine, dopexamine, salbutamol, terbutaline, fenoterol, orciprenaline, clenbuterol, salmeterol, formoterol), B-blockers, alpha-stimulants (midodrine, alpha-methyl-dopa, clonidine, rilmenidine, moxonidine), alpha-blockers (phentolamine, prazosin, urapidil), amphetamine, tyramine, ephedrine, selegiline, cocaine, imipramine.~* Impossibility to submit to the medical follow-up of the program for geographical, social or psychological reasons.~* Patient deprived of liberty or under guardianship.~* Patient with preventive background treatment of Cluster Headache (CH).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with Cluster Headache (CH) (Type: None): Patients with Cluster Headache (CH) will be included. They will have a Holter electrocardiogram during 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues